Although PDGFRα expression is variable in human livers (Supplementary Fig. S6), its contribution to response differences in clinical trials is unknown.65 Insights will be provided by the ongoing phase 3 trial evaluating valoctocogene roxaparvovec with prophylactic corticosteroids in participants with hemophilia A (NCT04323098). This evidence concerns the gene PDGFRA and hemophilia A.